Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
Study Findings: A head-to-head study published in JAMA Dermatology compared four FDA-approved neurotoxins—Jeuveau, Botox, Dysport, and Xeomin—showing that Jeuveau has a faster onset, stronger peak effect, and longer duration of efficacy for treating glabellar lines.
Market Impact: Since its launch, Jeuveau has rapidly gained market share, becoming the fastest-growing neurotoxin in the U.S. with over 14% market penetration and significant presence in aesthetic clinics.
Trade with 70% Backtested Accuracy
Analyst Views on EOLS
About EOLS
About the author
BofA Raises Teradyne Price Target to $260 Amid Strong Buy Rating
- Price Target Increase: BofA Securities raised Teradyne's price target from $250 to $260 while maintaining a Buy rating, reflecting confidence in the company's growth potential, with shares closing at $231.89 on Tuesday, indicating market recognition of its prospects.
- Alphabet Rating Upgrade: Raymond James increased Alphabet's price target from $315 to $400 and upgraded the rating from Outperform to Strong Buy, signaling optimism about the recovery of its advertising business, with shares closing at $328.38 on Wednesday, showcasing investor confidence in its future performance.
- Elanco Price Adjustment: Piper Sandler raised Elanco's price target from $24 to $30, upgrading the rating from Neutral to Overweight, reflecting expectations for increased demand for its animal health products, with shares closing at $24.30 on Wednesday, indicating a positive market outlook.
- Teledyne Price Target Boost: Needham increased Teledyne's price target from $615 to $700 while maintaining a Buy rating, demonstrating analyst confidence in its technology and market position, with shares closing at $621.79 on Wednesday, reflecting investor expectations for future growth.
Evolus Provides 2026 Net Revenue Guidance, Forecasts 13% Growth
- Strong 2025 Performance: Evolus anticipates fourth-quarter net revenues between $88.6 million and $90.6 million for 2025, reflecting a 12% to 15% year-over-year growth, indicating the company's ability to gain market share in a competitive environment.
- Sustained Profitability: The company reaffirms a positive non-GAAP operating income of $5 million to $7 million for Q4 2025, marking a significant milestone in achieving sustainable profitability, which is expected to continue into 2026.
- 2026 Revenue Guidance: Evolus projects net revenues for 2026 to be between $327 million and $337 million, representing an 11% to 13% growth from preliminary 2025 results, showcasing the company's confidence in future market growth.
- Long-Term Financial Outlook: Evolus updates its 2028 financial outlook, projecting total net revenues between $450 million and $500 million, reflecting a 15% to 19% CAGR, underscoring the strategic success in international market expansion and product diversification efforts.
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
- Full Exit: Stonepine Capital sold all 38,597 shares of ANI Pharmaceuticals in Q3, valued at approximately $2.52 million, marking a complete exit from the company as of September 30.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has risen 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase during the same period, indicating strong market competitiveness.
- Financial Growth: ANI Pharmaceuticals reported a 54% year-over-year revenue surge to $227.8 million in the latest quarter, with adjusted EBITDA jumping nearly 70% to $59.6 million, prompting management to raise full-year revenue guidance to $873 million.
- Investment Strategy Shift: The exit by Stonepine does not reflect a lack of confidence in ANI but rather a capital rotation, indicating a preference for earlier-stage biotech investments, which suggests a cautious outlook on ANI's future growth potential.
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead
RxSight's After-Hours Surge: RxSight shares jumped 18.1% after reporting a wider net loss and a 14% revenue decline, but improved its full-year revenue guidance and gross margin outlook.
Penumbra's Strong Performance: Penumbra's stock rose 16.4% following a strong Q3 with increased net income and revenue, along with a raised full-year revenue forecast.
Evolus Continues Gains: Evolus saw a 13.5% increase in after-hours trading after narrowing its net loss and reporting revenue growth, while reaffirming its full-year revenue guidance.
Modest Growth for Other Companies: CVRx and Cytek Biosciences also experienced after-hours gains, with CVRx reporting a slight improvement in losses and revenue growth, while Cytek reaffirmed its future revenue guidance despite a net loss.
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch
Partnership Announcement: Evolus, Inc. has appointed Dr. Benjamin Eskenazi as the lead consultant for the national launch of their new Evolysse™ hyaluronic acid filler line, emphasizing their commitment to patient safety and provider education.
Innovative Technology: The Evolysse™ fillers, utilizing Cold-X™ technology, are the first major advancement in hyaluronic acid dermal fillers in a decade, promising longer-lasting and natural-looking results, with FDA approval recently granted for Evolysse™ Form and Evolysse™ Smooth.
Evolus Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Stock Options and RSUs Granted: Evolus, Inc. has granted stock options and restricted stock units (RSUs) to newly hired employees, including 143,403 shares and 104,603 RSUs to the new Chief Financial Officer, Tatjana Mitchell, as part of their 2023 Inducement Incentive Plan.
Vesting and Exercise Details: The stock options have a 10-year term and vest over four years, with specific vesting schedules for both non-executive employees and Ms. Mitchell, who has different terms for her RSUs.
BofA Raises Teradyne Price Target to $260 Amid Strong Buy Rating
- Price Target Increase: BofA Securities raised Teradyne's price target from $250 to $260 while maintaining a Buy rating, reflecting confidence in the company's growth potential, with shares closing at $231.89 on Tuesday, indicating market recognition of its prospects.
- Alphabet Rating Upgrade: Raymond James increased Alphabet's price target from $315 to $400 and upgraded the rating from Outperform to Strong Buy, signaling optimism about the recovery of its advertising business, with shares closing at $328.38 on Wednesday, showcasing investor confidence in its future performance.
- Elanco Price Adjustment: Piper Sandler raised Elanco's price target from $24 to $30, upgrading the rating from Neutral to Overweight, reflecting expectations for increased demand for its animal health products, with shares closing at $24.30 on Wednesday, indicating a positive market outlook.
- Teledyne Price Target Boost: Needham increased Teledyne's price target from $615 to $700 while maintaining a Buy rating, demonstrating analyst confidence in its technology and market position, with shares closing at $621.79 on Wednesday, reflecting investor expectations for future growth.
Evolus Provides 2026 Net Revenue Guidance, Forecasts 13% Growth
- Strong 2025 Performance: Evolus anticipates fourth-quarter net revenues between $88.6 million and $90.6 million for 2025, reflecting a 12% to 15% year-over-year growth, indicating the company's ability to gain market share in a competitive environment.
- Sustained Profitability: The company reaffirms a positive non-GAAP operating income of $5 million to $7 million for Q4 2025, marking a significant milestone in achieving sustainable profitability, which is expected to continue into 2026.
- 2026 Revenue Guidance: Evolus projects net revenues for 2026 to be between $327 million and $337 million, representing an 11% to 13% growth from preliminary 2025 results, showcasing the company's confidence in future market growth.
- Long-Term Financial Outlook: Evolus updates its 2028 financial outlook, projecting total net revenues between $450 million and $500 million, reflecting a 15% to 19% CAGR, underscoring the strategic success in international market expansion and product diversification efforts.
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
- Full Exit: Stonepine Capital sold all 38,597 shares of ANI Pharmaceuticals in Q3, valued at approximately $2.52 million, marking a complete exit from the company as of September 30.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has risen 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase during the same period, indicating strong market competitiveness.
- Financial Growth: ANI Pharmaceuticals reported a 54% year-over-year revenue surge to $227.8 million in the latest quarter, with adjusted EBITDA jumping nearly 70% to $59.6 million, prompting management to raise full-year revenue guidance to $873 million.
- Investment Strategy Shift: The exit by Stonepine does not reflect a lack of confidence in ANI but rather a capital rotation, indicating a preference for earlier-stage biotech investments, which suggests a cautious outlook on ANI's future growth potential.
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead
RxSight's After-Hours Surge: RxSight shares jumped 18.1% after reporting a wider net loss and a 14% revenue decline, but improved its full-year revenue guidance and gross margin outlook.
Penumbra's Strong Performance: Penumbra's stock rose 16.4% following a strong Q3 with increased net income and revenue, along with a raised full-year revenue forecast.
Evolus Continues Gains: Evolus saw a 13.5% increase in after-hours trading after narrowing its net loss and reporting revenue growth, while reaffirming its full-year revenue guidance.
Modest Growth for Other Companies: CVRx and Cytek Biosciences also experienced after-hours gains, with CVRx reporting a slight improvement in losses and revenue growth, while Cytek reaffirmed its future revenue guidance despite a net loss.
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch
Partnership Announcement: Evolus, Inc. has appointed Dr. Benjamin Eskenazi as the lead consultant for the national launch of their new Evolysse™ hyaluronic acid filler line, emphasizing their commitment to patient safety and provider education.
Innovative Technology: The Evolysse™ fillers, utilizing Cold-X™ technology, are the first major advancement in hyaluronic acid dermal fillers in a decade, promising longer-lasting and natural-looking results, with FDA approval recently granted for Evolysse™ Form and Evolysse™ Smooth.
Evolus Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Stock Options and RSUs Granted: Evolus, Inc. has granted stock options and restricted stock units (RSUs) to newly hired employees, including 143,403 shares and 104,603 RSUs to the new Chief Financial Officer, Tatjana Mitchell, as part of their 2023 Inducement Incentive Plan.
Vesting and Exercise Details: The stock options have a 10-year term and vest over four years, with specific vesting schedules for both non-executive employees and Ms. Mitchell, who has different terms for her RSUs.
